Acceptability of the third dose of anti-SARS-CoV-2 vaccine co-administered with influenza vaccine: preliminary data in a sample of Italian HCWs

Stefanizzi, Pasquale; Martinelli, Andrea; Bianchi, Francesco Paolo; Migliore, Giovanni; Tafuri, Silvio

doi:10.1080/21645515.2021.2011652

Cited by 28 publications

(28 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is even more unclear whether this different acceptance (if any) may generate gender disparities in vaccination coverage. In line with our findings (reversed aOR males vs. females of 1.78 (95% CI: 1.50-2.12)), COVID-19/SIV vaccine co-administration was more prevalent among male healthcare workers with an OR 1.43 (95% CI: 1.22-1.67) [26]. SIV and pneumococcal vaccine co-administration in English/Welsh populations was more frequent (by approximately 6%) in men than in women, and this difference was present in all age-groups, while the between-sex difference in the general pneumococcal vaccination coverage rate was not statistically significant [51].…”

Section: Discussionsupporting

confidence: 91%

“…By contrast, in this study an inverse age-acceptance relationship was observed: each 1-year increase in age was associated with a 1.1% decrease in the odds of accepting simultaneous vaccine administration. In the above-mentioned study by Stefanizzi et al [26], the effect of age on concomitant COVID-19/SIV vaccine administration among healthcare workers was not statistically significant. In England and Wales, SIV and pneumococcal vaccine coadministration was highest in working-age adults, followed by the elderly and children [50].…”

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

“…A recent single-center study by Stefanizzi et al [26] reported a very high rate of co-administration of the third COVID-19 dose and SIV among healthcare workers. In particular, a total of 60.0% were co-administered both vaccines, while 26.2% and 13.8% of subjects chose to get only the COVID-19 vaccine and SIV, respectively [26]. This comparably high co-administration rate was likely driven by the selected study population of healthcare professionals who received appropriate and effective counseling.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Acceptance of COVID-19 and Influenza Vaccine Co-Administration: Insights from a Representative Italian Survey

Domnich

Grassi²,

Fallani

et al. 2022

JPM

View full text Add to dashboard Cite

Co-administration of coronavirus disease 2019 (COVID-19) and seasonal influenza vaccines has several advantages, has been advocated by various public health authorities and should be seen as an opportunity to increase the uptake of both vaccines. The objective of this survey was to quantify the acceptance of concomitant COVID-19/influenza vaccination and to identify its correlates in a representative sample of Italian adults. Of 2463 participants, a total of 22.9% were favorable to vaccine co-administration, while 16.6% declared their firm unwillingness to receive both vaccines simultaneously. The remaining 60.5% of subjects could be dubbed hesitant to some degree. Compliance with the primary COVID-19 vaccination schedule (adjusted proportional odds ratio (aOR) = 7.78), previous influenza vaccination (aOR = 1.89) and trust in public health institutions (aOR = 1.22) were the main determinants of positive attitudes toward vaccine co-administration. Other significant correlates included age, sex, perceived disease severity and vaccination risk–benefit, being offered a more personalized influenza vaccine and recent seeking for influenza-related information. In Italy, hesitancy toward COVID-19/influenza vaccine co-administration is common and appears to be higher than hesitancy toward either vaccine administered alone. This pattern is multifaceted and requires specific and tailored strategies, with public health institutions playing the central role.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Acceptance of COVID-19 and Influenza Vaccine Co-Administration: Insights from a Representative Italian Survey

Domnich

Grassi²,

Fallani

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…Preliminary data [ 80 ] from a large University Hospital in Bari (Italy) indicated very high compliance of healthcare workers with COVID-19/SIV co-administration: a total of 60% (1643/2740) received both the third COVID-19 dose and SIV simultaneously. A higher probability of co-administration was seen among physicians (OR 1.93) and residents (OR 2.10), while nurses displayed lower odds (OR 0.75).…”

Section: Public Acceptance Of Covid-19 and Influenza Vaccine Co-admin...mentioning

confidence: 99%

COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy

et al. 2022

View full text Add to dashboard Cite

SARS-CoV-2 and influenza are the main respiratory viruses for which effective vaccines are currently available. Strategies in which COVID-19 and influenza vaccines are administered simultaneously or combined into a single preparation are advantageous and may increase vaccination uptake. Here, we comprehensively review the available evidence on COVID-19/influenza vaccine co-administration and combination vaccine candidates from the standpoints of safety, immunogenicity, efficacy, policy and public acceptance. While several observational studies have shown that the trained immunity induced by influenza vaccines can protect against some COVID-19-related endpoints, it is not yet understood whether co-administration or combination vaccines can exert additive effects on relevant outcomes. In randomized controlled trials, co-administration has proved safe, with a reactogenicity profile similar to that of either vaccine administered alone. From the immunogenicity standpoint, the immune response towards four influenza strains and the SARS-CoV-2 spike protein in co-administration groups is generally non-inferior to that seen in groups receiving either vaccine alone. Several public health authorities have advocated co-administration. Different combination vaccine candidates are in (pre)-clinical development. The hesitancy towards vaccine co-administration or combination vaccines is a multifaceted phenomenon and may be higher than the acceptance of either vaccine administered separately. Public health implications are discussed.

show abstract

Did the health care vaccine mandate work? An evaluation of the impact of the COVID-19 vaccine mandate on vaccine uptake and infection risk in a large cohort of Canadian health care workers

Okpani,

Lockhart,

Barker

et al. 2024

American Journal of Infection Control

View full text Add to dashboard Cite

Acceptability of the third dose of anti-SARS-CoV-2 vaccine co-administered with influenza vaccine: preliminary data in a sample of Italian HCWs

Cited by 28 publications

References 6 publications

Acceptance of COVID-19 and Influenza Vaccine Co-Administration: Insights from a Representative Italian Survey

Acceptance of COVID-19 and Influenza Vaccine Co-Administration: Insights from a Representative Italian Survey

COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy

Did the health care vaccine mandate work? An evaluation of the impact of the COVID-19 vaccine mandate on vaccine uptake and infection risk in a large cohort of Canadian health care workers

Contact Info

Product

Resources

About